公开(公告)号：US20240148917A1

公开(公告)日：2024-05-09

申请号：US18249192

申请日：2021-10-18

Applicant: Zytox Therapeutics AB

Inventor： Amelie Eriksson Karlström ,  Kristina Westerlund ,  Hanna Tano

IPC: A61K51/08 ,  A61K47/60 ,  A61K47/64 ,  A61K47/66 ,  A61K49/00 ,  A61P35/00

CPC classification number: A61K51/088 ,  A61K47/60 ,  A61K47/64 ,  A61K47/665 ,  A61K49/0002 ,  A61P35/00

Abstract: The invention relates to a kit for targeting of a diagnostic or therapeutic agent to a target site comprising: (a) a first conjugate comprising (i) a targeting moiety capable of binding selectively to the target site; and (ii) a first hybridization probe moiety comprising a PNA oligomer; and (b) a second conjugate comprising (i) a second hybridization probe moiety comprising a complementary PNA oligomer; and (ii) a diagnostic agent or a therapeutic agent moiety; wherein the length of the complementary PNA oligomer in the second hybridization probe moiety is not more than 14 bases. The invention further relates to methods for delivering a diagnostic or therapeutic agent to a target site in mammals, as well as methods for the diagnosis or treatment of medical conditions, such as e.g. cancer, in mammals.